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We think the evidence supports a restrictive blood transfusion threshold using a haemoglobin 
concentration (Hb) trigger of 70 g/L in younger, less sick patients in ICUs, especially those without 
co-existing cardiorespiratory co-morbidity[1, 2]. More liberal transfusion could increase important 
complications without clinical benefit[3]. In addition, red blood cells are expensive and no trials have 
demonstrated their cost-effectiveness. Unfortunately, many of our patients are sick, older, and have 
cardiorespiratory co-morbidity. It is these patients in whom we think individualised transfusion 
threshold decisions may be needed. 
Physiological arguments against a blanket restrictive Hb trigger 
There is biological plausibility for maintaining higher Hb levels, and by inference, higher oxygen 
delivery in higher risk patients, such as those with cardiovascular disease and acute severe sepsis. 
Specifically, the frequent presence of both tachycardia and hypotension in the critically ill, the 
requirement for catecholamines that increase myocardial work, and the high coronary oxygen 
extraction ratio, support the argument for higher Hb values in the presence of coronary disease. 
Coronary oxygen supply-demand imbalance may result in “type II” myocardial infarction or injury. 
Troponin release is prevalent in the critically ill, and is associated with higher mortality[4, 5]. 
In sepsis, oxygen supply-demand imbalances may occur regionally, with arteriovenous shunting, 
resulting in a hypoxaemic microcirculation despite global haemodynamics appearing relatively 
normal[6, 7]. Red blood cell transfusion may improve oxygen content and availability by recruiting 
the microcirculation[8]. Many septic patients have cardiovascular co-morbidity, raising the possibility 
of a “double hit” from severe anaemia in this population. Is a transfusion trigger of 70g/L really safe 
for all of these cases? 
What does the high quality evidence tell us?  
The FOCUS trial [9] enrolled elderly patients with cardiovascular disease undergoing hip surgery and 
found no difference in a composite outcome of mortality or inability to walk independently at 60 
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days (OR liberal-strategy 1.01, 95% CI 0.84 to 1.22). This high quality trial is correctly quoted as 
evidence that restrictive transfusion practice is safe, but how restrictive? The mean (SD) restrictive 
Hb trigger was 79 (6) g/L and most patients were only exposed to Hb values <90g/L for <3 days. In 
fact the restrictive arm used individualised triggers based on patients’ symptoms and signs. FOCUS is 
therefore not strong evidence that 70g/L is “the new norm” for these patients.  
The TRICC and TRISS trials are the highest quality evidence in the critically ill, and both used a 
restrictive Hb trigger of 70g/L[1, 2]. Both reported underpowered cardiovascular and/or ischaemic 
heart disease sub-group analyses; these showed (non-significant) point estimates that favoured 
liberal practice (TRICC: ARR 4.0%, 95% CI -6.9 to 14.9; TRISS: RR 1.08, 95% CI 0.75 to 1.40).    
The median time to recruitment for TRISS was 21 hours after ICU admission, and 14 hours for TRICC, 
and in a smaller trial of older patients the delay was 96 hours[10]. This excluded the early period of 
critical illness when arguably the oxygen supply-demand balance may be most deranged.  The recent 
early goal-directed trials in sepsis (ProCESS, ARISE and PROMISE), which included the use of red cell 
transfusions when the Hb was  <100g/L and ScVO2 <70%, found no outcome benefit overall[11], but 
relatively few patients triggered the blood transfusion part of the algorithm. It also seems unlikely 
that many patients had Hb<70g/L during the intervention period. These trials were underpowered 
for patients with low ScVO2 and low Hb and, importantly, for patient sub-groups with comorbidity 
such as cardiac disease. The possibility of differential, potentially opposite, effects from fixed 
interventions in heterogeneous critically ill populations has been illustrated in relation to 
transfusion[12] (Figure 1). We are uncertain, therefore, that we have strong evidence that a fixed 
70g/L Hb trigger is safest for all patients.  
Are we ready for precision medicine in relation to transfusion?  
Mortality is not necessarily the best endpoint for blood transfusion trials in critically ill patients. 
Clinically important differences may occur that do not translate into mortality differences, or are 
undetectable without very large sample sizes. This is particularly relevant in critical care where 
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populations are heterogeneous in terms of comorbidity and acute pathology, and where multiple 
factors influence the risk of death. In addition to this, anaemia persists in many patients after critical 
illness[13], and may contribute to the post-ICU syndrome that we are only starting to understand. 
There is a strong association between transfusion and quality of life in chronic anaemia 
syndromes[14]; the same might be true in recovering critically ill patients. 
At present available methods for measuring cellular, tissue, or organ oxygenation status lack 
sensitivity and specificity. Perhaps the way forward is to explore novel measures of end organ 
perfusion to guide transfusion decisions. In relation to the heart, cardiac specific enzymes such as 
troponin I or MyC (Cardiac myosin binding protein C) may quantify myocardial damage; similarly 
continuous ECG monitoring could detect the ischaemic burden placed on the heart. Myocardial 
infarction or injury seems an especially relevant endpoint for patients with cardiovascular disease. 
The diagnosis of myocardial infarction in the context of critical illness is often subjective, and 
understanding what levels of biochemically quantified injury are important could lead to future 
“precision medicine” trials exploring whether interventions such as blood transfusion can modify 
these outcomes.  
Conclusion 
As is often the case there is common ground in the debate. We agree the evidence supports a 
default Hb trigger of 70 g/L for younger patients and those without cardiovascular disease (acute or 
chronic). For critically ill older patients, especially those with cardiac disease, we agree the general 
approach should be restrictive but are not sure that the evidence supports a “new norm” of 70g/L 
for all. We are not alone. An analysis of transfusion triggers in the international ABLE trial showed 
substantial variation, with ischaemic heart disease modifying behaviour[15]. Future studies need to 
develop strategies to inform precision medicine approaches that can be tested in trials in defined 
populations. This may enable evidence-based individualised transfusion therapy. Until then we will 
continue to require clinical judgement. 
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Legend for Figure 1:   
The effect of transfusion strategy on mortality is dependent on the presence or absence 
prerandomization of ischaemic heart disease. In the TRICC transfusion trigger trial[1], the effects of 
transfusion thresholds on 30-day mortality were significantly different and opposite depending on 
the presence or absence prerandomization of ischaemic heart disease (Breslow-Day test; p = .03). In 
patients with ischaemic heart disease (n = 257), the use of a restrictive transfusion strategy 
increased mortality compared with the use of a liberal strategy. In patients without ischaemic heart 
disease (n = 581), the use of a restrictive transfusion strategy decreased mortality compared with 
the use of a liberal strategy. For this analysis, data from the original and subsequent publications 
were combined. Reproduced with permission from Deans et al[12]. 
 
  
  
